Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477599 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL10956292 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL5772077 | 0.73 | KMT2A (0.62) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL5911726 | 0.73 | KMT2A (0.62) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL20001809 | 0.72 | IDO1 (0.55) | SMN1; SMN2LMNAHTT | |
| SCHEMBL31067669 | 0.72 | MAOB (0.71) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL17064305 | 0.72 | MAOB (0.71) | SMN1; SMN2LMNAHPGDALOX15TSHR | |
| SCHEMBL20001929 | 0.72 | ALDH1A1 (0.40) | SMN1; SMN2LMNAKMT2A | |
| SCHEMBL18137400 | 0.72 | IDO1 (0.49) | — | |
| SCHEMBL11603161 | 0.72 | KMT2A (0.63) | SMN1; SMN2LMNAHPGDALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | SMN1; SMN2 2220/4885LMNA 4252/4885HPGD 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.